LiDCO Group Plc
25 April 2005


For immediate release                                             25 April 2005


                                LiDCO GROUP PLC
                           ("LiDCO" or "the Company")

                   Appointment of new Group Finance Director


LiDCO Group plc, (AIM: LID) the UK-based cardiovascular monitoring company, is
pleased to announce today the appointment of Hugh Jullian McGarel-Groves as
Group Finance Director and to the Board of the Company with effect from 10th May
2005.

Over the past12 years, Mr McGarel-Groves, aged 52, has held Finance Director
roles in the private healthcare sector at Hospital Corporation International,
Medical Services International (Cromwell Hospital) and Nestor Healthcare (BNA).
He started his career as a chartered accountant with KPMG in London, and then
held senior finance positions at BP, Guinness and Sedgwick.  His breadth of
experience includes 4 years managing his own specialist engineering company.

Mr McGarel-Groves is a director of Home Farm Services Ltd. No other details are
required to be disclosed under paragraph F schedule 2 of the AIM Rules with
respect to Mr McGarel-Groves.

As provided in his service agreement, the Company will grant Mr McGarel-Groves
250,000 options under its share option scheme on the 10th May 2005, the
commencement date of his employment.

Commenting on today's announcement, Dr Terry O'Brien, Chief Executive of LiDCO
said: "I am delighted to welcome Hugh to the Board of LiDCO.  Hugh has worked in
both large public international corporations and smaller private organisations.
He has broad experience of both operational and corporate finance matters.  This
combination of experiences coupled to his knowledge of healthcare, will be
particularly valuable as LiDCO moves into the next stage of its growth and
commercial development."

Hugh McGarel-Groves said: "I am joining LiDCO at an exciting time for the
Company and I am impressed by the clinical strength of LiDCO's product, and by
the company's growing international distribution network and registration
portfolio."

For further information please contact:

LiDCO Group Plc
Terry O'Brien (CEO) terry@lidco.com                             020 7749 1500

Buchanan Communications
Tim Anderson, Mary-Jane Johnson, James Strong                   020 7466 5000


Notes for Editors

About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London where the Company
maintains a research base.

The Company's manufacturing facility is in Hoxton, London and its current
products are:

•      LiDCOplus and PulseCO monitors: computer-based platforms for displaying a
range of real-time, continuous hemodynamic parameters including cardiac output,
oxygen delivery and fluid volume;

•      LiDCO disposables: accurately determine cardiac output in a
minimally-invasive manner.

Distribution Network:

The Company has achieved registration of its products in 13 markets in Europe,
the USA and Japan.  It sells direct to the NHS in the UK, and through a
worldwide network of specialty critical care distributors.

Background to the recently published clinical trial: Better than standard care -
(EGDT) improves outcome in high risk surgery patients:

The results of a major trial at St George's Hospital, London using LiDCO's
minimally invasive monitoring technology were presented during the 25th
International Symposium on Intensive Care and Emergency Medicine in Brussels
(21st to 25th March). The results have revealed the following:

a) Savings in the cost of treating patients amounting to an average of £4,000
per patient.  Extrapolated nationally, this would equate to a saving of £500
million per annum for the NHS

b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62
patients, an average of more than 10 bed days per patient

c) The savings in cost and time were associated with a significant reduction in
medical complications (particularly infections - which were halved) through the
use of LiDCO's minimally invasive technology to improve tissue oxygen levels
following surgery.


                      This information is provided by RNS
            The company news service from the London Stock Exchange